• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    MannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/6/25 7:10:45 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email
    8-K
    false000089946000008994602025-08-062025-08-06

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 06, 2025

     

     

    MannKind Corporation

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    000-50865

    13-3607736

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    1 Casper Street

     

    Danbury, Connecticut

     

    06810

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (818) 661-5000

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.01 per share

     

    MNKD

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02. Results of Operations and Financial Condition.

    On August 6, 2025, MannKind Corporation issued a press release, a copy of which is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

    Item 9.01. Financial Statements and Exhibits.

     

    Exhibit 99.1

    Press release dated August 6, 2025

     

     

    Exhibit 104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    MannKind Corporation

     

    Date: August 6, 2025

    By:

    /s/ David Thomson, Ph.D., J.D.

    David Thomson, Ph.D., J.D.

    Corporate Vice President, General Counsel and Secretary

     

     


    Get the next $MNKD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNKD

    DatePrice TargetRatingAnalyst
    7/16/2025$9.00Buy
    H.C. Wainwright
    4/10/2025$12.00Outperform
    Mizuho
    2/10/2025$11.00Outperform
    Wedbush
    12/20/2024$9.00Overweight
    Wells Fargo
    12/19/2024$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    9/9/2024$7.00 → $8.00Outperform
    Leerink Partners
    6/13/2024$8.00Buy
    Rodman & Renshaw
    10/10/2023$10.00Outperform
    Wedbush
    More analyst ratings

    $MNKD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

    Strengthens MannKind's capital structure with flexible, long-term, non-dilutive fundingMannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, and funds managed by Blackstone ("Blackstone") today announced that they have entered into an up to $500 million strategic financing agreement. The financing agreement provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies

    8/6/25 7:10:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

    2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD 2024Advanced pipeline: Submitted sBLA for Afrezza® in pediatric populationMNKD-101: NTM global Phase 3 trial (ICoN-1) enrollment ahead of scheduleMNKD-201: Plan to initiate Phase 2 clinical trial for IPF by YE 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the second quarter 2025 and provided a business update. "The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes," said Mi

    8/6/25 7:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its second quarter 2025 financial results will be released before market open on August 6, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days. About MannKindMannKind Corporation (NASDAQ:MNKD) focuses on the developme

    7/30/25 4:05:00 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    SEC Filings

    View All

    SEC Form 10-Q filed by MannKind Corporation

    10-Q - MANNKIND CORP (0000899460) (Filer)

    8/6/25 7:15:26 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MANNKIND CORP (0000899460) (Filer)

    8/6/25 7:10:45 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - MANNKIND CORP (0000899460) (Filer)

    5/19/25 5:02:22 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Financials

    Live finance-specific insights

    View All

    MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

    2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD 2024Advanced pipeline: Submitted sBLA for Afrezza® in pediatric populationMNKD-101: NTM global Phase 3 trial (ICoN-1) enrollment ahead of scheduleMNKD-201: Plan to initiate Phase 2 clinical trial for IPF by YE 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the second quarter 2025 and provided a business update. "The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes," said Mi

    8/6/25 7:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its second quarter 2025 financial results will be released before market open on August 6, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days. About MannKindMannKind Corporation (NASDAQ:MNKD) focuses on the developme

    7/30/25 4:05:00 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

    Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024Advanced pipeline: Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025MNKD-101: NTM global Phase 3 trial enrollment on track for interim analysisMNKD-201: Expect to continue to next phase of global development in 2H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter 2025 and provided a business update. "The first quarter was marked by strong y

    5/8/25 8:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    2/13/24 5:08:11 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    1/22/24 12:56:57 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    2/9/23 11:25:13 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief People & Workpl Officer Tross Stuart A was granted 12,755 shares, increasing direct ownership by 1% to 1,079,013 units (SEC Form 4)

    4 - MANNKIND CORP (0000899460) (Issuer)

    8/6/25 8:00:03 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Binder Steven B. covered exercise/tax liability with 19,383 shares and sold $296,946 worth of shares (75,367 units at $3.94), decreasing direct ownership by 10% to 830,508 units (SEC Form 4)

    4 - MANNKIND CORP (0000899460) (Issuer)

    7/17/25 8:51:11 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP Chief Medical Officer Blank Burkhard covered exercise/tax liability with 9,556 shares, decreasing direct ownership by 2% to 460,791 units (SEC Form 4)

    4 - MANNKIND CORP (0000899460) (Issuer)

    7/17/25 8:48:47 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Mannkind with a new price target

    H.C. Wainwright resumed coverage of Mannkind with a rating of Buy and set a new price target of $9.00

    7/16/25 7:57:36 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Mannkind with a new price target

    Mizuho initiated coverage of Mannkind with a rating of Outperform and set a new price target of $12.00

    4/10/25 12:42:30 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Mannkind with a new price target

    Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $11.00

    2/10/25 7:01:41 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Leadership Updates

    Live Leadership Updates

    View All

    MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

    MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

    1/5/22 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care